FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2735952875> ?p ?o ?g. }

• W2735952875 endingPage "910" @default.
• W2735952875 startingPage "903" @default.
• W2735952875 abstract "Systemic inflammatory and autoimmune diseases (SIADs) associated with myelodysplastic syndromes are often difficult to treat. Corticosteroids are efficient but only usually at high doses. The use of biologics needs to be specified. In a French multicenter retrospective study, we analyzed the efficacy and safety of biologics (tumor necrosis factor-α [TNF-α] antagonists, tocilizumab, rituximab and anakinra) for SIADs associated with myelodysplastic syndromes (MDSs). Clinical, biological and overall treatment responses were evaluated. When several lines of treatment were used, data were analyzed before and at the end of each treatment line and were pooled to compare overall response among steroids, disease-modifying anti-rheumatic drugs (DMARDs) and biologics. We included 29 patients (median age 67 years [interquartile range 62–76], 83% males) with MDS-related SIADs treated with at least one biologic. The MDSs were predominantly refractory anemia with excess blasts 1 (38%) and refractory cytopenia with multilineage dysplasia (21%). The SIADs were mainly arthritis (n = 6; 20%), relapsing polychondritis (n = 8; 30%) and vasculitis (n = 10; 34%). During a 3-year median follow-up (IQR 1.3–4.5), a total of 114 lines of treatments were used for all patients: steroids alone (22%), DMARDs (23%), TNF-α antagonists (14%), anakinra (10%), rituximab (10%), tocilizumab (7%) and azacytidine (9%). Considering all 114 lines, overall response (complete and partial) was shown in 54% cases. Overall response was more frequent with steroids (78%) and rituximab (66%) than DMARDs (45%) and other biologics (33%) (p < 0.05). Rituximab had better response in vasculitis and TNF-α antagonists in arthritis. During follow-up, 20 patients (71%) presented at least one severe infection. This nationwide study demonstrates the efficacy of steroids for SIAD-associated MDSs but a high frequency of steroid dependence. The response to biologics seems low, but rituximab and azacytidine seem promising." @default.
• W2735952875 created "2017-07-21" @default.
• W2735952875 creator A5004039946 @default.
• W2735952875 creator A5005717120 @default.
• W2735952875 creator A5006955984 @default.
• W2735952875 creator A5007605254 @default.
• W2735952875 creator A5007732660 @default.
• W2735952875 creator A5009777179 @default.
• W2735952875 creator A5014020914 @default.
• W2735952875 creator A5014838075 @default.
• W2735952875 creator A5017844579 @default.
• W2735952875 creator A5021661813 @default.
• W2735952875 creator A5036756845 @default.
• W2735952875 creator A5041077575 @default.
• W2735952875 creator A5045287052 @default.
• W2735952875 creator A5046448910 @default.
• W2735952875 creator A5052607095 @default.
• W2735952875 creator A5053505571 @default.
• W2735952875 creator A5055188307 @default.
• W2735952875 creator A5060012820 @default.
• W2735952875 creator A5062082959 @default.
• W2735952875 creator A5062315921 @default.
• W2735952875 creator A5065172277 @default.
• W2735952875 creator A5066489166 @default.
• W2735952875 creator A5067369506 @default.
• W2735952875 creator A5067988271 @default.
• W2735952875 creator A5075707786 @default.
• W2735952875 creator A5082407460 @default.
• W2735952875 creator A5082959305 @default.
• W2735952875 creator A5087386909 @default.
• W2735952875 creator A5087525573 @default.
• W2735952875 date "2017-09-01" @default.
• W2735952875 modified "2023-10-17" @default.
• W2735952875 title "Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients" @default.
• W2735952875 cites W1483180137 @default.
• W2735952875 cites W1965469610 @default.
• W2735952875 cites W1991345036 @default.
• W2735952875 cites W2023052004 @default.
• W2735952875 cites W2038981426 @default.
• W2735952875 cites W2045969166 @default.
• W2735952875 cites W2051726694 @default.
• W2735952875 cites W2065270636 @default.
• W2735952875 cites W2079256024 @default.
• W2735952875 cites W2087854083 @default.
• W2735952875 cites W2091247622 @default.
• W2735952875 cites W2101234143 @default.
• W2735952875 cites W2136746124 @default.
• W2735952875 cites W2142219378 @default.
• W2735952875 cites W2264982566 @default.
• W2735952875 cites W2318075407 @default.
• W2735952875 cites W2588993427 @default.
• W2735952875 doi "https://doi.org/10.1016/j.autrev.2017.07.003" @default.
• W2735952875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28705782" @default.
• W2735952875 hasPublicationYear "2017" @default.
• W2735952875 type Work @default.
• W2735952875 sameAs 2735952875 @default.
• W2735952875 citedByCount "28" @default.
• W2735952875 countsByYear W27359528752018 @default.
• W2735952875 countsByYear W27359528752019 @default.
• W2735952875 countsByYear W27359528752020 @default.
• W2735952875 countsByYear W27359528752021 @default.
• W2735952875 countsByYear W27359528752022 @default.
• W2735952875 countsByYear W27359528752023 @default.
• W2735952875 crossrefType "journal-article" @default.
• W2735952875 hasAuthorship W2735952875A5004039946 @default.
• W2735952875 hasAuthorship W2735952875A5005717120 @default.
• W2735952875 hasAuthorship W2735952875A5006955984 @default.
• W2735952875 hasAuthorship W2735952875A5007605254 @default.
• W2735952875 hasAuthorship W2735952875A5007732660 @default.
• W2735952875 hasAuthorship W2735952875A5009777179 @default.
• W2735952875 hasAuthorship W2735952875A5014020914 @default.
• W2735952875 hasAuthorship W2735952875A5014838075 @default.
• W2735952875 hasAuthorship W2735952875A5017844579 @default.
• W2735952875 hasAuthorship W2735952875A5021661813 @default.
• W2735952875 hasAuthorship W2735952875A5036756845 @default.
• W2735952875 hasAuthorship W2735952875A5041077575 @default.
• W2735952875 hasAuthorship W2735952875A5045287052 @default.
• W2735952875 hasAuthorship W2735952875A5046448910 @default.
• W2735952875 hasAuthorship W2735952875A5052607095 @default.
• W2735952875 hasAuthorship W2735952875A5053505571 @default.
• W2735952875 hasAuthorship W2735952875A5055188307 @default.
• W2735952875 hasAuthorship W2735952875A5060012820 @default.
• W2735952875 hasAuthorship W2735952875A5062082959 @default.
• W2735952875 hasAuthorship W2735952875A5062315921 @default.
• W2735952875 hasAuthorship W2735952875A5065172277 @default.
• W2735952875 hasAuthorship W2735952875A5066489166 @default.
• W2735952875 hasAuthorship W2735952875A5067369506 @default.
• W2735952875 hasAuthorship W2735952875A5067988271 @default.
• W2735952875 hasAuthorship W2735952875A5075707786 @default.
• W2735952875 hasAuthorship W2735952875A5082407460 @default.
• W2735952875 hasAuthorship W2735952875A5082959305 @default.
• W2735952875 hasAuthorship W2735952875A5087386909 @default.
• W2735952875 hasAuthorship W2735952875A5087525573 @default.
• W2735952875 hasBestOaLocation W27359528752 @default.
• W2735952875 hasConcept C119060515 @default.
• W2735952875 hasConcept C126322002 @default.
• W2735952875 hasConcept C141071460 @default.
• W2735952875 hasConcept C17991360 @default.

• next